This site is intended for healthcare professionals
Liver cirrhosis
EACCME® accredited podcast series

Why early AATD diagnosis is key to optimal liver disease management

Read time: 90 mins
Last updated: 1st Apr 2024
Published:2nd Apr 2023

Listen and learn: AATD podcast series

Earn 1.5 CME credits by listening to this EACCME®-accredited podcast series and achieving a score of 70% or higher in the final knowledge assessment

  • What is AATD and how does it impact the liver and the lung?
  • AATD genotypes involved in liver disease
  • Screening, diagnosis, and guideline recommendations for AATD management
  • Treatment options for AATD-associated liver disease and current unmet needs


Course overview

Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition that predisposes individuals to developing severe liver and lung disease. Early screening and diagnosis are essential for optimal disease management, however many clinicians are unaware of the condition to begin with.

Refresh your clinical knowledge of AATD with our panel of experts, Professor Strnad, Professor Teckman and Dr Miravitlles in this EACCME®-accredited podcast series reviewing screening, diagnosis, management, and treatment of AATD.

Upon completion of the podcast series, you will have the opportunity to test your knowledge in our interactive assessment. Achieve a score of 70% or higher in this assessment to receive your 1.5 CME credits. 

Podcast Content outline Time
(90 mins total)
1 What is AATD and how does it impact the liver and the lung? 24 mins
2 AATD genotypes involved in liver disease 27 mins
3 Screening, diagnosis, and guideline recommendations for AATD management 19 mins
4 Treatment options for AATD-associated liver disease and current unmet needs 20 mins

Learning objectives

On completion of this module, participants will understand:

  • Aetiology, pathology and genetic basis of AATD
  • Gold-standard guideline recommendations for screening and diagnosis of AATD
  • Strategies for treatment and management of AATD liver disease
  • Unmet needs in people with AATD and the future of AATD clinical research

Meet the experts

Professor Pavel Strnad.pngProfessor Pavel Strnad

Clinic for Gastroenterology at the University Hospital RWTH Aachen, Germany

Professor Pavel Strnad is a full professor and leading physician at the University Hospital Aachen, Germany. Professor Strnad is heading a European initiative for the study of alpha1-antitrypsin deficiency-associated liver disease and is helping develop new therapies for this rare disorder. His scientific interests include metabolic liver disease, liver cirrhosis and complications, keratins and iron metabolism. His clinical focus is on novel treatments, end-stage liver disease and liver transplantation. 


Professor Jeffrey Teckman.pngProfessor Jeffrey Teckman

Division of Pediatric Gastroenterology in the Department of Pediatrics, Saint Louis University School of Medicine, United States

Professor Jeffrey Teckman is Professor of Pediatrics and Biochemistry at Saint Louis University School of Medicine and Cardinal Glennon Children's Hospital, and was named as the Drs. James and Patricia Monteleone Endowed Chair in Pediatric Gastroenterology and Hepatology. He has studied liver injury and the model of alpha-1-antitrypsin deficiency for 30 years and has participated in clinical research studies in a variety of diseases including alpha-1, cystic fibrosis, hepatitis C, hepatitis B, and metabolic diseases. He holds several patents in liver disease and has been a leader in bringing new therapies of alpha-1 disease to clinical trials.

Dr Marc Miravitlles.pngDr Marc Miravitlles

Hospital Universitari Vall d’Hebron / Vall d’Hebron Research Institute, Barcelona, Spain 

Dr Marc Miravitlles is senior researcher and consultant at Vall d’Hebron University Hospital in Barcelona. He was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and Guidelines Director of the ERS. He has acted as a consultant for the development of international guidelines of COPD, including the American Thoracic Society (ATS)/ERS guidelines on exacerbations of COPD and the ERS statement on management of respiratory disease in alpha-1 antitrypsin deficiency (AATD). He was the founder of the Spanish Registry for AATD in 1992 and is the co-chair of EARCO, the European Alpha-1 Antitrypsin Deficiency Research Collaboration (EARCO) Registry of the ERS since 2018.

Faculty Disclosures

Dr Marc Miravitlles - Consultancy fees from Atriva Therapeutics, CSL Behring, Inhibrx, Mereo Biopharma (relationship terminated), Spin Therapeutics (relationship terminated), ONO Pharma (relationship terminated), Takeda, Novo Nordisk and Grifols.Grants/research suport from Grifols. Speaker’s bureau fees from Kamada, Takeda, CSL Behring and Grifols.

Professor Pavel Strnad - Advisory board or panel fees from Albireo, Dicerna, Intellia, Takeda, Ono Pharmaceuticals, CSL Behring, Grifols Inc. Consultancy fees from Dicerna, Intellia, Takeda, Ono Pharmaceuticals and Sanofi.Grants/research support from CSL Behring, Grifols, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals and Dicerna Pharmaceuticals.

Professor Jeffrey Teckman - Advisory board or panel fees from Takeda and BioMarin. Consultancy fees from Arrowhead, Dicerna, BioMarin, NovoNordisk, Beam Therapeutics, Camp4 Therapeutics, Centessa, Intellia, KorroBio, NeuBase, Takeda, UniQure and Vertex.Grants research support from Arrowhead, BioMarin, Camp4 Therapeutics, KorroBio, Takeda, UniQure and Vertex.


This content has been developed independently of the sponsor, Takeda, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.